Research programme: solid tumour therapies - ViRexx
Alternative Names: Occlusin; Occlusin 500 Artificial Embolization Device; Occlusin 500 Device; TactinLatest Information Update: 27 Apr 2024
At a glance
- Originator ViRexx Medical Corp
- Class Albumins
- Mechanism of Action Platelet aggregation stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Liver cancer; Solid tumours; Uterine leiomyoma
Most Recent Events
- 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
- 16 Jul 2016 No recent reports of development identified for preclinical development in Liver-cancer in Canada (Intrahepatic)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Canada (IV-injection)